Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up.
Larissa I van der WindtJob KlumperEmilie V J van Limburg StirumJanneke van 't HooftMadelon van WelyAleid G van Wassenaer-LeemhuisEva PajkrtMartijn A Oudijknull nullPublished in: BMJ open (2024)
The Medical Research Ethics Committee from Amsterdam UMC confirmed that de Medical Research Involving Human Subjects Act (Dutch WMO-law) did not apply to our study (W21_386 # 21.431). Results will be published in a peer-reviewed journal and shared with stakeholders and participants. This protocol is published before analysis of the results.
Keyphrases
- preterm birth
- gestational age
- randomized controlled trial
- study protocol
- healthcare
- low birth weight
- endothelial cells
- public health
- preterm infants
- clinical trial
- induced pluripotent stem cells
- meta analyses
- big data
- systematic review
- machine learning
- placebo controlled
- open label
- combination therapy
- pluripotent stem cells
- phase iii
- global health